# Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma

> **NCT00911196** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 200 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **OTHER:** Retrospective analysis of already archived samples

## Key facts

- **NCT ID:** NCT00911196
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911196, "Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00911196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*